In the precision-targeted therapy space for non-small cell lung cancer (NSCLC), EGFR exon 20 insertion mutations (ex20ins) have long been viewed as one of the most difficult-to-treat niche targets with high unmet clinical demand.

Unlike classical EGFR mutations, patients with ex20ins mutations generally develop resistance to first-, second-, and third-generation EGFR-TKIs. For years, first-line treatment has relied on chemotherapy, offering limited survival benefits and few therapeutic options—leaving a substantial unmet clinical need.

As domestic innovative drug development accelerates, this long-dormant niche segment is now undergoing significant transformation. With the breakthroughs of two leading domestic targeted therapies—Dizal Pharma's sunvozertinib and Allist Pharma's furmonertinib—the domestic EGFR ex20ins treatment landscape is poised for a major shift.

From a capital markets perspective, the ex20ins indication represents a core battleground for these two listed companies to unlock a second growth curve and differentiate their valuations within the industry.

Currently, sunvozertinib's first-line indication is in the priority review sprint phase. According to data from the Insight database, furmonertinib's application for first-line treatment of ex20ins NSCLC was also submitted on September 20, marking the beginning of a direct head-to-head race between the two domestic champions.

Sunvozertinib Boasts Positive Phase III Data; Furmonertinib Shows Stronger Early-Stage Results

EGFR ex20ins is the third most common EGFR mutation subtype, accounting for 10%–12% of all EGFR-mutant NSCLC patients, with approximately 39,000 new cases annually in China.

Traditional first-line chemotherapy yields a median progression-free survival (PFS) of only 6–7 months, with limited efficacy and significant side effects. The previous domestic first-line standard of care relied primarily on Johnson & Johnson's amivantamab combined with chemotherapy—a regimen that earned high-level guideline recommendations based on superior overall survival (OS) data, but required chemotherapy, leading to poor patient compliance and high tolerability demands that limited its suitability for elderly, frail, or brain-metastatic patients.

Oral, chemotherapy-free targeted monotherapy has emerged as the core clinical and market demand, creating a prime window of opportunity for sunvozertinib and furmonertinib to rise.

Sunvozertinib, independently developed by Dizal Pharma, is a highly selective, irreversible EGFR-TKI whose key technical highlight is precise targeting of ex20ins mutations while sparing wild-type EGFR, significantly reducing the toxicity profile of traditional targeted therapies.

It is currently the only domestic oral ex20ins-targeted drug with complete positive Phase III first-line data. Clinical results show that sunvozertinib monotherapy as first-line treatment for advanced NSCLC with EGFR ex20ins achieves a median PFS of 10.3 months—a significant improvement over the 7.5 months seen with traditional chemotherapy—reducing the risk of disease progression by 35% with statistical significance.

The objective response rate (ORR) reaches 58.9%, with a median duration of response (DOR) of 11.2 months, meaning nearly 60% of patients experience significant tumor shrinkage with durable efficacy.

Additionally, sunvozertinib's commercial foundation is largely established. Its second-line indication was approved in China in August 2023, and in July 2025 it secured accelerated approval from the U.S. FDA—making it the first domestic ex20ins-targeted drug approved in both China and the U.S. The second-line indication has also been successfully included in China's National Reimbursement Drug List (NRDL), greatly improving patient access and laying a solid clinical and market foundation for the first-line indication's rollout.

Furmonertinib, on the other hand, is Allist Pharma's core independently developed third-generation EGFR-TKI. Compared with sunvozertinib, its R&D progress in the ex20ins space has been relatively slower.

Currently, the public data supporting furmonertinib's first-line ex20ins use comes from the Phase Ib FAVOUR study. Clinical data show an ORR of 78.6% in the overall population and a median DOR of 15.2 months, with short-term response rates and durability of response surpassing the Phase III data disclosed for sunvozertinib.

For the high-incidence brain metastasis patient population, furmonertinib's advantages are even more pronounced—its blood-brain barrier penetration rate far exceeds that of comparable TKIs, enabling effective intracranial disease control and addressing a key shortfall of most ex20ins-targeted therapies.

However, it must be noted that furmonertinib currently lacks confirmatory Phase III first-line data. Its core efficacy evidence is derived from a small-scale Phase Ib trial with limited sample size. The data's persuasiveness and broad-spectrum patient suitability still require validation from the upcoming FURMO-004 global multicenter Phase III study results—this remains its biggest disadvantage relative to sunvozertinib.

On the commercialization front, furmonertinib's ex20ins second-line indication was officially approved in February 2026 but has not yet been included in the NRDL, keeping near-term patient costs high and constraining market penetration speed.

Furmonertinib Enters First-Line Ex20ins Review; Domestic Duo Set for Direct Competition

Competition in the innovative drug space is fundamentally a race against time. The pace of indication approval directly determines first-mover advantages, market positioning, and share priority—and serves as a core reference metric for capital market valuation.

Leveraging the strong positive results of the WU-KONG28 study, sunvozertinib's first-line EGFR ex20ins indication application was formally accepted by the NMPA in May 2026 and simultaneously included in the priority review program.

Following the typical pace of domestic priority review for innovative drugs, combined with the drug's complete clinical data, low safety risk, and the urgent unmet clinical need, industry consensus suggests sunvozertinib is likely to receive first-line approval between late 2026 and early 2027—potentially becoming the first domestically produced targeted drug approved as first-line monotherapy for ex20ins.

Previously, industry expectations were that furmonertinib's first-line indication would lag sunvozertinib by one to two years. However, according to Insight database data, on September 20, 2026, furmonertinib formally submitted its first-line EGFR ex20ins treatment application—just four months after sunvozertinib's May 2026 submission.

Both core domestic drugs are now in the approval pipeline, with both likely to secure first-line approvals between late 2026 and the first half of 2027. The approval timelines heavily overlap, significantly compressing the window for sunvozertinib to exclusively capture the initial market dividend. It can no longer establish a long-term monopoly in the domestic oral market, and both will engage in head-to-head competition across approval timing, clinical evidence, and commercialization execution.

It is worth noting that although both drugs are high-quality innovative targeted therapies, the commercialization systems of the two companies differ significantly—a gap that could reshape the competitive landscape and potentially offset furmonertinib's approval timing disadvantage.

Dizal Pharma is a typical research-driven innovative drug company. Its core strengths lie in target discovery, drug design, and clinical development, while its weakness is insufficient self-commercialization capability. The company currently lacks a mature national sales team, and historical product promotion has relied heavily on external partnerships.

After sunvozertinib's second-line indication launch, NRDL inclusion and strong clinical data drove steady volume growth, but overall sales scale has been constrained by channel limitations. Although the recent partnership with AstraZeneca addresses overseas commercialization challenges, the domestic market still relies on self-built teams and cooperative channels. Compared with traditional pharmaceutical companies, Dizal's terminal coverage, academic promotion, and physician penetration capabilities are notably weaker—meaning post-approval first-line volume ramp-up may fall short of expectations in the short term.

In contrast, Allist Pharma is a leading domestic player in NSCLC targeted therapy commercialization. Furmonertinib's classical EGFR mutation indication has already achieved annual sales exceeding RMB 5 billion, supported by a complete nationwide sales network with top-tier terminal management, NRDL negotiation experience, and channel maintenance capabilities.

Following first-line approval, the company is well-positioned to leverage existing physician relationships and terminal channels to drive product uptake.

Looking at the broader picture, from late 2026 through 2027, the domestic EGFR ex20ins first-line space is likely to see a critical window of concurrent approvals for both drugs. Sunvozertinib, benefiting from an earlier submission, priority review progress, and mature complete Phase III data, is expected to secure approval slightly ahead—capturing short-term first-mover market advantages.

However, furmonertinib has essentially closed the progress gap, with approval timing only slightly delayed, and the previously anticipated prolonged market vacancy will not materialize. Sunvozertinib will be unable to exclusively reap the domestic market dividend, limited to only a short-term, finite first-mover premium.

As both companies' first-line indication approvals enter their final sprint phases, the question of who will seize the commanding heights of domestic targeted therapy remains open. We will continue to monitor developments closely.